Sponsors: []Modifications:     31A-22-640.(1)  For purposes of this section "pharmacy benefits manager or coordinator" means aperson or entity that provides pharmacy benefit management services as defined in Section

49-20-502

 on behalf of an insurer as defined in Subsection 

31A-22-636

(1).(2)  An insurer and an insurer's pharmacy benefits manager or coordinator is subject tothe pharmacy audit provisions of Section 

58-17b-622

.:(a)  require each responder to comply with the pharmacy audit provisions of Section

58-17b-622

; and(b)(7)(8)providespharmacy benefit management services as defined in Section 

49-20-502

    58-17b-622.(1)  For purposes of this section:(a)  "Audit" means a review of the records of a pharmacy by or on behalf of an entitythat finances or reimburses the cost of health care services or pharmaceutical products.(b)  "Entity" includes:(i)  a pharmacy benefits manager or coordinator;(ii)  a health benefit plan;(iii)  a third party administrator as defined in Section 

31A-1-301

;(iv)  a state agency; or(v)  a company, group, or agent that represents, or is engaged by, one of the entitiesdescribed in Subsections (1)(b)(i) through (iv).(c)  "Health benefit plan" means:(i)  a health benefit plan as defined in Section 

31A-1-301

; or(ii)  a health, dental, medical, Medicare supplement, or conversion program offeredunder Title 49, Chapter 20, Public Employees' Benefit and Insurance Program Act.(2) (a)  Except as provided in Subsection (2)(b), this section applies to:(i)  a contract for the audit of a pharmacy entered into, amended, or renewed on or afterJuly 1, 2012; and(ii)  an entity that conducts an audit of the pharmacy records of a pharmacy licensedunder this chapter.(b)  This section does not apply to an audit of pharmacy records for the purpose ofdetecting fraud in the state Medicaid program if the audit is conducted:(i)  under the provisions of Title 63J, Chapter 4a, Office of Inspector General ofMedicaid Services; and(ii)  by the Office of the Inspector General, or its designee.(3) (a)  An audit that involves clinical or professional judgement shall be conducted byor in consultation with a pharmacist licensed under this chapter.(b)  If an audit is conducted on site at a pharmacy, the entity conducting the audit:(i)  shall give the pharmacy 14 days advanced written notice of:(A)  the audit; and(B)  the prescription numbers included in the audit; and(ii)  may not audit a pharmacy during the first seven calendar days of the month, unlessthe pharmacy agrees to the timing of the audit.(c)  An entity may not audit claims:(i)  submitted more than 24 months prior to the audit, unless required by federal law; or(ii)  that exceed:(A)  the lesser of:(I)  1% of the average monthly prescription claims submitted by the pharmacy to theentity conducting the audit; or(II)  200 prescription claims; or(B)  the number of claims for which the entity has substantiated or documenteddiscrepancies.(4)  An entity may not:(a)  include dispensing fees in the calculations of overpayments;(b)  recoup funds for a clerical or record keeping error in a required document unless:(i)  the entity can provide proof of intent to commit fraud; or(ii)  the clerical error resulted in financial harm to the entity or a consumer;(c)  collect any funds, charge-backs, or penalties until the audit and all appeals are final;(d)  charge interest on disputed claims during the audit and any appeals to the audit;(e)  receive payment for the audit based on a percentage of the amount recovered in theaudit; or(f)  except when required by state or federal law, share audit information or pharmacyrecords with another entity that is conducting a subsequent or new audit of the pharmacy.(5)  A pharmacy subject to an audit may use the following records to validate a claimfor a prescription, refill, or change in a prescription:(a)  electronic or physical copies of records of a health care facility, or a health careprovider with prescribing authority; and(b)  any prescription that complies with state law.(6) (a)  An entity that audits a pharmacy shall provide the pharmacy with a preliminaryaudit report, delivered to the pharmacy or its corporate office of record within 60 days aftercompletion of the audit.(b)  A pharmacy has 30 days following receipt of the preliminary audit report torespond to questions, provide additional documentation, and comment on and clarify findingsof the audit.(7)  If an audit results in the dispute or denial of a claim, the entity conducting the auditshall allow the pharmacy to re-submit a claim using any commercially reasonable method,including fax, mail, or electronic claims submission.(8) (a)  Within 120 days after the completion of the appeals process under Subsection(9), a final audit report shall be delivered to the pharmacy or its corporate office of record, andto the health benefit plan for whom the audit was conducted.(b)  The final audit report shall include a disclosure of any money recovered by theentity that conducted the audit.(9) (a)  An entity that audits a pharmacy shall establish a written appeals process forappealing a preliminary audit report and a final audit report, and shall provide the pharmacywith notice of the written appeals process at the time the notice of audit is provided to thepharmacy.(b)  The appeals process under Subsection (9)(a) shall offer the pharmacy the option tosubmit an appeal of the final audit report:(i)  directly to the health benefit plan;(ii)  to mediation; or(iii)  to a civil action.(10)  A pharmacy or pharmacist injured as a result of a violation of this section maybring a civil action against the person, corporation, or business entity that violated this sectionfor recovery of damages occurring as a result of the violation.Full text:



Utah State Legislature












Legislators

By Session (1896-Current)
Alphabetical (Historical)
Find by Address/Map
More


Bills

Bills/Bill Requests
Passed Bills
2017 Bills

Keyword Search
Reading Calendars
Tracking Service
More


Committees

All Committees
Appropriations
Commissions

Independent Legislative Ethics Commission
Interim
Standing
Subcommittees
Task Forces
Bills In Committees


Utah Code / Constitution


Title/Chapter/Section
Keyword Search 

Utah Constitution
Laws of Utah 1851-ongoing
Utah Territorial Laws 
More


Senate

Main Page 
About The Senate 
Leadership 
Roster 
Seating Chart 
District Maps 
Extraordinary Sessions 
Reading Calendars 
Past Floor Debates 
Senate Journals 


House

Main Page
About the House 
Leadership 
Roster 
Seating Chart 
District Maps 
Reading Calendars 
Past Floor Debates 
Journals 
Conflict of Interest Forms 


Legislative Guide 

Legislative Guide
Civic Programs
GRAMA (Records Requests)


Publications

Search Publications
Appropriations
Audits
Bagels & Briefings
Briefing Papers
Digest of Legislation
Legislative Drafting Manual

Journals

Interim Highlights

Legislative Rules
GRAMA (Records Requests)
Public Email
State Organization Charts
YouTube Channel
Requests for Proposals and Legal Notices
More


Legislative Histories

Legislative History Resources
How to Research
Bill Drafting/Research Files (1990-Ongoing)

Working Bills (1896-1989)
Interim Committee Histories (1990-Ongoing) 
Journals
Past House Floor Debates
Past Senate Floor Debates
More


Staff Offices

All Legislative Offices
Auditor General
Fiscal Analyst
Printing
Research and General Counsel
Staff Awards
Job Opportunities
More


Links of Interest

Utah Administrative Rules
Courts
Utah State Capitol
State of Utah
Federal Legislation
More






 

Download Zipped Introduced WordPerfect HB0076.ZIP
[Status][Bill Documents][Fiscal Note][Bills Directory]


H.B. 76





            
1

    
 PHARMACY AUDIT RIGHTS



            
2

    
2012 GENERAL SESSION

            
3

    
STATE OF UTAH

            
4

    


 Chief Sponsor:  Evan J. Vickers



            
5

    



Senate Sponsor:  






____________





            
6

    

            
7

    
 LONG TITLE
            
8

    
 General Description:
            
9

    
    This bill requires health benefit plans, the Public Employees' Benefits and Insurance
            
10

    
Program, and pharmacy benefit managers to implement certain pharmacy audit
            
11

    
procedures when auditing pharmacy claims.
            
12

    
 Highlighted Provisions:
            
13

    
    This bill:
            
14

    
    .    requires a health insurer and a pharmacy benefits manager for a health insurer to
            
15

    
comply with pharmacy audit rights established in the Pharmacy Practice Act;
            
16

    
    .    requires the Public Employees' Benefit and Insurance Program to comply with
            
17

    
pharmacy audit rights established in the Pharmacy Practice Act;
            
18

    
    .    amends the definition of pharmacy benefits manager in the Pharmacy Practice Act
            
19

    
to be consistent with the definition of pharmacy benefits manager in the Pharmacy
            
20

    
Benefits Manager Act; and
            
21

    
    .    enacts pharmacy audit rights in the Pharmacy Practices Act that include:
            
22

    
        .    definitions;
            
23

    
        *    requirements for notice of an audit;
            
24

    
        .    limits on the types of claims that may be audited;
            
25

    
        *    requirements for an entity conducting an audit; and
            
26

    
        *    procedures to appeal an audit.
            
27

    
 Money Appropriated in this Bill:

            
28


    
    None
            
29

    
 Other Special Clauses:
            
30

    
    None
            
31

    
 Utah Code Sections Affected:
            
32

    
AMENDS:
            
33

    
     49-20-503, as enacted by Laws of Utah 2011, Chapter 83
            
34

    
     58-17b-102, as last amended by Laws of Utah 2010, Chapter 101
            
35

    
ENACTS:
            
36

    
     31A-22-640, Utah Code Annotated 1953
            
37

    
     58-17b-622, Utah Code Annotated 1953
            
38

    

            
39

    
Be it enacted by the Legislature of the state of Utah:
            
40

    
    Section 1.  
Section  
31A-22-640

 is enacted to read:
            
41

    
     31A-22-640.  Pharmacy benefit management services -- Audit restrictions.
            
42

    
    (1)  For purposes of this section "pharmacy benefits manager or coordinator" means a
            
43

    
person or entity that provides pharmacy benefit management services as defined in Section
            
44

    


49-20-502

 on behalf of an insurer as defined in Subsection 

31A-22-636

(1).
            
45

    
    (2)  An insurer and an insurer's pharmacy benefits manager or coordinator is subject to
            
46

    
the pharmacy audit provisions of Section 

58-17b-622

.
            
47

    
    Section 2.  
Section  
49-20-503

 is amended to read:
            
48

    
     49-20-503.  Request for proposals for pharmacy benefits manager for Public
            
49

    
 Employees' Benefit and Insurance Program.
            
50

    
    (1)  When the board issues a request for proposals for a pharmacy benefits manager to
            
51

    
provide pharmacy benefits management services for the program, the request for proposals
            
52

    
shall:
            
53

    
    (a)  require each responder to comply with the pharmacy audit provisions of Section
            
54

    


58-17b-622

; and
            
55

    
    (b)  provide each responder with the option to include, among the billing options
            
56

    
proposed, a billing option that complies with the requirements described in this section.
            
57

    
    (2)  The billing option described in Subsection (1) shall require the pharmacy benefits
            
58

    
manager to, on at least a monthly basis, submit to the board an invoice for all pharmacy

            
59


    
services paid by the pharmacy benefits manager on behalf of the program since the last request
            
60

    
for payment or reimbursement.
            
61

    
    (3)  The invoice described in Subsection (2) shall state, as a separate item from any
            
62

    
other amount:
            
63

    
    (a)  the total amount due to the pharmacy benefits manager for all pharmacy services
            
64

    
billed in the invoice; and
            
65

    
    (b)  the total amount paid by the pharmacy benefits manager for the same pharmacy
            
66

    
services for which payment is sought in that invoice.
            
67

    
    Section 3.  
Section  
58-17b-102

 is amended to read:
            
68

    
     58-17b-102.  Definitions.
            
69

    
    In addition to the definitions in Section 

58-1-102

, as used in this chapter:
            
70

    
    (1)  "Administering" means:
            
71

    
    (a)  the direct application of a prescription drug or device, whether by injection,
            
72

    
inhalation, ingestion, or by any other means, to the body of a human patient or research subject
            
73

    
by another person; or
            
74

    
    (b)  the placement by a veterinarian with the owner or caretaker of an animal or group
            
75

    
of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other
            
76

    
means directed to the body of the animal by the owner or caretaker in accordance with written
            
77

    
or verbal directions of the veterinarian.
            
78

    
    (2)  "Adulterated drug or device" means a drug or device considered adulterated under
            
79

    
21 U.S.C.S. Sec. 351 (2003).
            
80

    
    (3) (a)  "Analytical laboratory" means a facility in possession of prescription drugs for
            
81

    
the purpose of analysis.
            
82

    
    (b)  "Analytical laboratory" does not include a laboratory possessing prescription drugs
            
83

    
used as standards and controls in performing drug monitoring or drug screening analysis if the
            
84

    
prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid
            
85

    
components, organic solvents, or inorganic buffers at a concentration not exceeding one
            
86

    
milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic
            
87

    
use.
            
88

    
    (4)  "Animal euthanasia agency" means an agency performing euthanasia on animals by
            
89

    
the use of prescription drugs.

            
90


    
    (5)  "Automated pharmacy systems" includes mechanical systems which perform
            
91

    
operations or activities, other than compounding or administration, relative to the storage,
            
92

    
packaging, dispensing, or distribution of medications, and which collect, control, and maintain
            
93

    
all transaction information.
            
94

    
    (6)  "Beyond use date" means the date determined by a pharmacist and placed on a
            
95

    
prescription label at the time of dispensing that indicates to the patient or caregiver a time
            
96

    
beyond which the contents of the prescription are not recommended to be used.
            
97

    
    [(8)] (7)  "Board of pharmacy" or "board" means the Utah State Board of Pharmacy
            
98

    
created in Section 

58-17b-201

.
            
99

    
    [(7)] (8)  "Branch pharmacy" means a pharmacy or other facility in a rural or medically
            
100

    
underserved area, used for the storage and dispensing of prescription drugs, which is dependent
            
101

    
upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and
            
102

    
approved by the division as the parent pharmacy.
            
103

    
    (9)  "Centralized prescription processing" means the processing by a pharmacy of a
            
104

    
request from another pharmacy to fill or refill a prescription drug order or to perform
            
105

    
processing functions such as dispensing, drug utilization review, claims adjudication, refill
            
106

    
authorizations, and therapeutic interventions.
            
107

    
    (10)  "Class A pharmacy" means a pharmacy located in Utah that is authorized as a
            
108

    
retail pharmacy to compound or dispense a drug or dispense a device to the public under a
            
109

    
prescription order.
            
110

    
    (11)  "Class B pharmacy":
            
111

    
    (a)  means a pharmacy located in Utah:
            
112

    
    (i)  that is authorized to provide pharmaceutical care for patients in an institutional
            
113

    
setting; and
            
114

    
    (ii)  whose primary purpose is to provide a physical environment for patients to obtain
            
115

    
health care services; and
            
116

    
    (b) (i)  includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and
            
117

    
    (ii)  pharmaceutical administration and sterile product preparation facilities.
            
118

    
    (12)  "Class C pharmacy" means a pharmacy located in Utah that is authorized to
            
119

    
engage in the manufacture, production, wholesale, or distribution of drugs or devices.
            
120

    
    (13)  "Class D pharmacy" means a nonresident pharmacy.

            
121


    
    (14)  "Class E pharmacy" means all other pharmacies.
            
122

    
    (15)  "Closed-door pharmacy" means a pharmacy that provides pharmaceutical care to a
            
123

    
defined and exclusive group of patients who have access to the services of the pharmacy
            
124

    
because they are treated by or have an affiliation with a specific entity, including a health
            
125

    
maintenance organization or an infusion company, but not including a hospital pharmacy, a
            
126

    
retailer of goods to the general public, or the office of a practitioner.
            
127

    
    (16)  "Collaborative pharmacy practice" means a practice of pharmacy whereby one or
            
128

    
more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or
            
129

    
more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical
            
130

    
care functions authorized by the practitioner or practitioners under certain specified conditions
            
131

    
or limitations.
            
132

    
    (17)  "Collaborative pharmacy practice agreement" means a written and signed
            
133

    
agreement between one or more pharmacists and one or more practitioners that provides for
            
134

    
collaborative pharmacy practice for the purpose of drug therapy management of patients and
            
135

    
prevention of disease of human subjects.
            
136

    
    (18) (a)  "Compounding" means the preparation, mixing, assembling, packaging, or
            
137

    
labeling of a limited quantity drug, sterile product, or device:
            
138

    
    (i)  as the result of a practitioner's prescription order or initiative based on the
            
139

    
practitioner, patient, or pharmacist relationship in the course of professional practice;
            
140

    
    (ii)  for the purpose of, or as an incident to, research, teaching, or chemical analysis and
            
141

    
not for sale or dispensing; or
            
142

    
    (iii)  in anticipation of prescription drug orders based on routine, regularly observed
            
143

    
prescribing patterns.
            
144

    
    (b)  "Compounding" does not include:
            
145

    
    (i)  the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to
            
146

    
another pharmacist or pharmaceutical facility;
            
147

    
    (ii)  the preparation by a pharmacist or pharmacy intern of any prescription drug in a
            
148

    
dosage form which is regularly and commonly available from a manufacturer in quantities and
            
149

    
strengths prescribed by a practitioner; or
            
150

    
    (iii)  the preparation of a prescription drug, sterile product, or device which has been
            
151

    
withdrawn from the market for safety reasons.

            
152


    
    (19)  "Confidential information" has the same meaning as "protected health
            
153

    
information" under the Standards for Privacy of Individually Identifiable Health Information,
            
154

    
45 C.F.R. Parts 160 and 164.
            
155

    
    (20)  "Controlled substance" has the same definition as in Section 

58-37-2

.
            
156

    
    (21)  "Dietary supplement" has the same meaning as Public Law Title 103, Chapter
            
157

    
417, Sec. 3a(ff) which is incorporated by reference.
            
158

    
    (22)  "Dispense" means the interpretation, evaluation, and implementation of a
            
159

    
prescription drug order or device or nonprescription drug or device under a lawful order of a
            
160

    
practitioner in a suitable container appropriately labeled for subsequent administration to or use
            
161

    
by a patient, research subject, or an animal.
            
162

    
    (23)  "Distribute" means to deliver a drug or device other than by administering or
            
163

    
dispensing.
            
164

    
    (24) (a)  "Drug" means:
            
165

    
    (i)  a substance recognized in the official United States Pharmacopoeia, Official
            
166

    
Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
            
167

    
supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
            
168

    
prevention of disease in humans or animals;
            
169

    
    (ii)  a substance that is required by any applicable federal or state law or rule to be
            
170

    
dispensed by prescription only or is restricted to administration by practitioners only;
            
171

    
    (iii)  a substance other than food intended to affect the structure or any function of the
            
172

    
body of humans or other animals; and
            
173

    
    (iv)  substances intended for use as a component of any substance specified in
            
174

    
Subsections (24)(a)(i), (ii), (iii), and (iv).
            
175

    
    (b)  "Drug" does not include dietary supplements.
            
176

    
    (25)  "Drug product equivalent" means a drug product that is designated as the
            
177

    
therapeutic equivalent of another drug product in the Approved Drug Products with
            
178

    
Therapeutic Equivalence Evaluations prepared by the Center for Drug Evaluation and Research
            
179

    
of the Federal Food and Drug Administration.
            
180

    
    (26)  "Drug regimen review" includes the following activities:
            
181

    
    (a)  evaluation of the prescription drug order and patient record for:
            
182

    
    (i)  known allergies;

            
183


    
    (ii)  rational therapy-contraindications;
            
184

    
    (iii)  reasonable dose and route of administration; and
            
185

    
    (iv)  reasonable directions for use;
            
186

    
    (b)  evaluation of the prescription drug order and patient record for duplication of
            
187

    
therapy;
            
188

    
    (c)  evaluation of the prescription drug order and patient record for the following
            
189

    
interactions:
            
190

    
    (i)  drug-drug;
            
191

    
    (ii)  drug-food;
            
192

    
    (iii)  drug-disease; and
            
193

    
    (iv)  adverse drug reactions; and
            
194

    
    (d)  evaluation of the prescription drug order and patient record for proper utilization,
            
195

    
including over- or under-utilization, and optimum therapeutic outcomes.
            
196

    
    (27)  "Drug sample" means a prescription drug packaged in small quantities consistent
            
197

    
with limited dosage therapy of the particular drug, which is marked "sample", is not intended to
            
198

    
be sold, and is intended to be provided to practitioners for the immediate needs of patients for
            
199

    
trial purposes or to provide the drug to the patient until a prescription can be filled by the
            
200

    
patient.
            
201

    
    (28)  "Electronic signature" means a trusted, verifiable, and secure electronic sound,
            
202

    
symbol, or process attached to or logically associated with a record and executed or adopted by
            
203

    
a person with the intent to sign the record.
            
204

    
    (29)  "Electronic transmission" means transmission of information in electronic form or
            
205

    
the transmission of the exact visual image of a document by way of electronic equipment.
            
206

    
    (30)  "Extern" means a college of pharmacy student enrolled in a college coordinated
            
207

    
practical experience program in a health care setting under the supervision of a preceptor, as
            
208

    
defined in this act, and approved by a college of pharmacy.
            
209

    
    (31)  "Hospital pharmacy" means a pharmacy providing pharmaceutical care to
            
210

    
inpatients of a general acute hospital or specialty hospital licensed by the Department of Health
            
211

    
under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act.
            
212

    
    (32)  "Legend drug" has the same meaning as prescription drug.
            
213

    
    (33)  "Licensed pharmacy technician" means an individual licensed with the division,

            
214


    
that may, under the supervision of a pharmacist, perform the activities involved in the
            
215

    
technician practice of pharmacy.
            
216

    
    (34)  "Manufacturer" means a person or business physically located in Utah licensed to
            
217

    
be engaged in the manufacturing of drugs or devices.
            
218

    
    (35) (a)  "Manufacturing" means:
            
219

    
    (i)  the production, preparation, propagation, conversion, or processing of a drug or
            
220

    
device, either directly or indirectly, by extraction from substances of natural origin or
            
221

    
independently by means of chemical or biological synthesis, or by a combination of extraction
            
222

    
and chemical synthesis, and includes any packaging or repackaging of the substance or labeling
            
223

    
or relabeling of its container; and
            
224

    
    (ii)  the promotion and marketing of such drugs or devices.
            
225

    
    (b)  "Manufacturing" includes the preparation and promotion of commercially available
            
226

    
products from bulk compounds for resale by pharmacies, practitioners, or other persons.
            
227

    
    (c)  "Manufacturing" does not include the preparation or compounding of a drug by a
            
228

    
pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation,
            
229

    
compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical
            
230

    
analysis.
            
231

    
    (36)  "Medical order" means a lawful order of a practitioner which may include a
            
232

    
prescription drug order.
            
233

    
    (37)  "Medication profile" or "profile" means a record system maintained as to drugs or
            
234

    
devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to analyze
            
235

    
the profile to provide pharmaceutical care.
            
236

    
    (38)  "Misbranded drug or device" means a drug or device considered misbranded under
            
237

    
21 U.S.C.S. Sec. 352 (2003).
            
238

    
    (39) (a)  "Nonprescription drug" means a drug which:
            
239

    
    (i)  may be sold without a prescription; and
            
240

    
    (ii)  is labeled for use by the consumer in accordance with federal law.
            
241

    
    (b)  "Nonprescription drug" includes homeopathic remedies.
            
242

    
    (40)  "Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a
            
243

    
person in Utah.
            
244

    
    (41)  "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service.

            
245


    
    (42)  "Out-of-state mail service pharmacy" means a pharmaceutical facility located
            
246

    
outside the state that is licensed and in good standing in another state, that:
            
247

    
    (a)  ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in
            
248

    
this state pursuant to a lawfully issued prescription;
            
249

    
    (b)  provides information to a patient in this state on drugs or devices which may
            
250

    
include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses;
            
251

    
or
            
252

    
    (c)  counsels pharmacy patients residing in this state concerning adverse and therapeutic
            
253

    
effects of drugs.
            
254

    
    (43)  "Patient counseling" means the written and oral communication by the pharmacist
            
255

    
or pharmacy intern of information, to the patient or caregiver, in order to ensure proper use of
            
256

    
drugs, devices, and dietary supplements.
            
257

    
    (44)  "Pharmaceutical administration facility" means a facility, agency, or institution in
            
258

    
which:
            
259

    
    (a)  prescription drugs or devices are held, stored, or are otherwise under the control of
            
260

    
the facility or agency for administration to patients of that facility or agency;
            
261

    
    (b)  prescription drugs are dispensed to the facility or agency by a licensed pharmacist
            
262

    
or pharmacy intern with whom the facility has established a prescription drug supervising
            
263

    
relationship under which the pharmacist or pharmacy intern provides counseling to the facility
            
264

    
or agency staff as required, and oversees drug control, accounting, and destruction; and
            
265

    
    (c)  prescription drugs are professionally administered in accordance with the order of a
            
266

    
practitioner by an employee or agent of the facility or agency.
            
267

    
    (45) (a)  "Pharmaceutical care" means carrying out the following in collaboration with a
            
268

    
prescribing practitioner, and in accordance with division rule:
            
269

    
    (i)  designing, implementing, and monitoring a therapeutic drug plan intended to
            
270

    
achieve favorable outcomes related to a specific patient for the purpose of curing or preventing
            
271

    
the patient's disease;
            
272

    
    (ii)  eliminating or reducing a patient's symptoms; or
            
273

    
    (iii)  arresting or slowing a disease process.
            
274

    
    (b)  "Pharmaceutical care" does not include prescribing of drugs without consent of a
            
275

    
prescribing practitioner.

            
276


    
    (46)  "Pharmaceutical facility" means a business engaged in the dispensing, delivering,
            
277

    
distributing, manufacturing, or wholesaling of prescription drugs or devices within or into this
            
278

    
state.
            
279

    
    (47) (a)  "Pharmaceutical wholesaler or distributor" means a pharmaceutical facility
            
280

    
engaged in the business of wholesale vending or selling of any prescription drug or device to
            
281

    
other than the consumer or user of the prescription drug or device, which the pharmaceutical
            
282

    
facility has not produced, manufactured, compounded, or dispensed.
            
283

    
    (b)  "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical
            
284

    
facility carrying out the following business activities:
            
285

    
    (i)  intracompany sales;
            
286

    
    (ii)  the sale, purchase, or trade of a prescription drug or device, or offer to sell,
            
287

    
purchase or trade a prescription drug or device between hospitals or other health care facilities
            
288

    
that are under common ownership or control of the management and operation of the facilities;
            
289

    
    (iii)  the sale, purchase, or trade of a prescription drug or device, or offer to sell,
            
290

    
purchase, or trade a prescription drug or device for emergency medical reasons, or to supply
            
291

    
another pharmaceutical facility to alleviate a temporary shortage; or
            
292

    
    (iv)  the distribution of a prescription drug or device as a sample by representatives of a
            
293

    
manufacturer.
            
294

    
    (48)  "Pharmacist" means an individual licensed by this state to engage in the practice
            
295

    
of pharmacy.
            
296

    
    (49)  "Pharmacist-in-charge" means a pharmacist currently licensed in good standing
            
297

    
who accepts responsibility for the operation of a pharmacy in conformance with all laws and
            
298

    
rules pertinent to the practice of pharmacy and the distribution of drugs, and who is personally
            
299

    
in full and actual charge of the pharmacy and all personnel.
            
300

    
    (50)  "Pharmacist preceptor" means a licensed pharmacist in good standing with two or
            
301

    
more years of licensed experience.  The preceptor serves as a teacher, example of professional
            
302

    
conduct, and supervisor of interns in the professional practice of pharmacy.
            
303

    
    (51)  "Pharmacy" means any place where:
            
304

    
    (a)  drugs are dispensed;
            
305

    
    (b)  pharmaceutical care is provided;
            
306

    
    (c)  drugs are processed or handled for eventual use by a patient; or

            
307


    
    (d)  drugs are used for the purpose of analysis or research.
            
308

    
    (52)  "Pharmacy benefits manager or coordinator" means a person or entity that
            
309

    
[administers the prescription drug or device portion of a health insurance plan] provides
            
310

    
pharmacy benefit management services as defined in Section 

49-20-502

 on behalf of a
            
311

    
self-insured employer, insurance company, health maintenance organization, or other plan
            
312

    
sponsor, as defined by rule.
            
313

    
    (53)  "Pharmacy intern" means an individual licensed by this state to engage in practice
            
314

    
as a pharmacy intern.
            
315

    
    (54)  "Pharmacy technician training program" means an approved technician training
            
316

    
program providing education for pharmacy technicians.
            
317

    
    (55) (a)  "Practice as a licensed pharmacy technician" means engaging in practice as a
            
318

    
pharmacy technician under the general supervision of a licensed pharmacist and in accordance
            
319

    
with a scope of practice defined by division rule made in collaboration with the board.
            
320

    
    (b)  "Practice as a licensed pharmacy technician" does not include:
            
321

    
    (i)  performing a drug utilization review, prescription drug order clarification from a
            
322

    
prescriber, final review of the prescription and prescribed drug prepared for dispensing,
            
323

    
dispensing of the drug, or counseling a patient with respect to a prescription drug;
            
324

    
    (ii)  counseling regarding nonprescription drugs and dietary supplements unless
            
325

    
delegated by the supervising pharmacist; or
            
326

    
    (iii)  receiving new prescription drug orders when communicating telephonically or
            
327

    
electronically unless the original information is recorded so the pharmacist may review the
            
328

    
prescription drug order as transmitted.
            
329

    
    (56)  "Practice of pharmacy" includes the following:
            
330

    
    (a)  providing pharmaceutical care;
            
331

    
    (b)  collaborative pharmacy practice in accordance with a collaborative pharmacy
            
332

    
practice agreement;
            
333

    
    (c)  compounding, packaging, labeling, dispensing, administering, and the coincident
            
334

    
distribution of prescription drugs or devices, provided that the administration of a prescription
            
335

    
drug or device is:
            
336

    
    (i)  pursuant to a lawful order of a practitioner when one is required by law; and
            
337

    
    (ii)  in accordance with written guidelines or protocols:

            
338


    
    (A)  established by the licensed facility in which the prescription drug or device is to be
            
339

    
administered on an inpatient basis; or
            
340

    
    (B)  approved by the division, in collaboration with the board and the Physicians
            
341

    
Licensing Board, created in Section 

58-67-201

, if the prescription drug or device is to be
            
342

    
administered on an outpatient basis solely by a licensed pharmacist;
            
343

    
    (d)  participating in drug utilization review;
            
344

    
    (e)  ensuring proper and safe storage of drugs and devices;
            
345

    
    (f)  maintaining records of drugs and devices in accordance with state and federal law
            
346

    
and the standards and ethics of the profession;
            
347

    
    (g)  providing information on drugs or devices, which may include advice relating to
            
348

    
therapeutic values, potential hazards, and uses;
            
349

    
    (h)  providing drug product equivalents;
            
350

    
    (i)  supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy
            
351

    
technicians;
            
352

    
    (j)  providing patient counseling, including adverse and therapeutic effects of drugs;
            
353

    
    (k)  providing emergency refills as defined by rule;
            
354

    
    (l)  telepharmacy; and
            
355

    
    (m)  formulary management intervention.
            
356

    
    (57)  "Practice of telepharmacy" means the practice of pharmacy through the use of
            
357

    
telecommunications and information technologies.
            
358

    
    (58)  "Practice of telepharmacy across state lines" means the practice of pharmacy
            
359

    
through the use of telecommunications and information technologies that occurs when the
            
360

    
patient is physically located within one jurisdiction and the pharmacist is located in another
            
361

    
jurisdiction.
            
362

    
    (59)  "Practitioner" means an individual currently licensed, registered, or otherwise
            
363

    
authorized by the appropriate jurisdiction to prescribe and administer drugs in the course of
            
364

    
professional practice.
            
365

    
    (60)  "Prescribe" means to issue a prescription:
            
366

    
    (a)  orally or in writing; or
            
367

    
    (b)  by telephone, facsimile transmission, computer, or other electronic means of
            
368

    
communication as defined by division rule.

            
369


    
    (61)  "Prescription" means an order issued:
            
370

    
    (a)  by a licensed practitioner in the course of that practitioner's professional practice or
            
371

    
by collaborative pharmacy practice agreement; and
            
372

    
    (b)  for a controlled substance or other prescription drug or device for use by a patient
            
373

    
or an animal.
            
374

    
    (62)  "Prescription device" means an instrument, apparatus, implement, machine,
            
375

    
contrivance, implant, in vitro reagent, or other similar or related article, and any component
            
376

    
part or accessory, which is required under federal or state law to be prescribed by a practitioner
            
377

    
and dispensed by or through a person or entity licensed under this chapter or exempt from
            
378

    
licensure under this chapter.
            
379

    
    (63)  "Prescription drug" means a drug that is required by federal or state law or rule to
            
380

    
be dispensed only by prescription or is restricted to administration only by practitioners.
            
381

    
    (64)  "Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs
            
382

    
and devices to the general public.
            
383

    
    (65)  "Self-audit" means an internal evaluation of a pharmacy to determine compliance
            
384

    
with this chapter.
            
385

    
    (66)  "Supervising pharmacist" means a pharmacist who is overseeing the operation of
            
386

    
the pharmacy during a given day or shift.
            
387

    
    (67)  "Supportive personnel" means unlicensed individuals who:
            
388

    
    (a)  may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed
            
389

    
pharmacy technician in nonjudgmental duties not included in the definition of the practice of
            
390

    
pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as
            
391

    
those duties may be further defined by division rule adopted in collaboration with the board;
            
392

    
and
            
393

    
    (b)  are supervised by a pharmacist in accordance with rules adopted by the division in
            
394

    
collaboration with the board.
            
395

    
    (68)  "Unlawful conduct" is as defined in Sections 

58-1-501

 and 

58-17b-501

.
            
396

    
    (69)  "Unprofessional conduct" is as defined in Sections 

58-1-501

 and 

58-17b-502

 and
            
397

    
may be further defined by rule.
            
398

    
    (70)  "Veterinary pharmaceutical facility" means a pharmaceutical facility that
            
399

    
dispenses drugs intended for use by animals or for sale to veterinarians for the administration

            
400


    
for animals.
            
401

    
    Section 4.  
Section  
58-17b-622

 is enacted to read:
            
402

    
     58-17b-622.  Pharmacy benefit management services -- Auditing of pharmacy
            
403

    
 records -- Appeals.
            
404

    
    (1)  For purposes of this section:
            
405

    
    (a)  "Audit" means a review of the records of a pharmacy by or on behalf of an entity
            
406

    
that finances or reimburses the cost of health care services or pharmaceutical products.
            
407

    
    (b)  "Entity" includes:
            
408

    
    (i)  a pharmacy benefits manager or coordinator;
            
409

    
    (ii)  a health benefit plan;
            
410

    
    (iii)  a third party administrator as defined in Section 

31A-1-301

;
            
411

    
    (iv)  a state agency; or
            
412

    
    (v)  a company, group, or agent that represents, or is engaged by, one of the entities
            
413

    
described in Subsections (1)(b)(i) through (iv).
            
414

    
    (c)  "Health benefit plan" means:
            
415

    
    (i)  a health benefit plan as defined in Section 

31A-1-301

; or
            
416

    
    (ii)  a health, dental, medical, Medicare supplement, or conversion program offered
            
417

    
under Title 49, Chapter 20, Public Employees' Benefit and Insurance Program Act.
            
418

    
    (2) (a)  Except as provided in Subsection (2)(b), this section applies to:
            
419

    
    (i)  a contract for the audit of a pharmacy entered into, amended, or renewed on or after
            
420

    
July 1, 2012; and
            
421

    
    (ii)  an entity that conducts an audit of the pharmacy records of a pharmacy licensed
            
422

    
under this chapter.
            
423

    
    (b)  This section does not apply to an audit of pharmacy records for the purpose of
            
424

    
detecting fraud in the state Medicaid program if the audit is conducted:
            
425

    
    (i)  under the provisions of Title 63J, Chapter 4a, Office of Inspector General of
            
426

    
Medicaid Services; and
            
427

    
    (ii)  by the Office of the Inspector General, or its designee.
            
428

    
    (3) (a)  An audit that involves clinical or professional judgement shall be conducted by
            
429

    
or in consultation with a pharmacist licensed under this chapter.
            
430

    
    (b)  If an audit is conducted on site at a pharmacy, the entity conducting the audit:

            
431


    
    (i)  shall give the pharmacy 14 days advanced written notice of:
            
432

    
    (A)  the audit; and
            
433

    
    (B)  the prescription numbers included in the audit; and
            
434

    
    (ii)  may not audit a pharmacy during the first seven calendar days of the month, unless
            
435

    
the pharmacy agrees to the timing of the audit.
            
436

    
    (c)  An entity may not audit claims:
            
437

    
    (i)  submitted more than 24 months prior to the audit, unless required by federal law; or
            
438

    
    (ii)  that exceed:
            
439

    
    (A)  the lesser of:
            
440

    
    (I)  1% of the average monthly prescription claims submitted by the pharmacy to the
            
441

    
entity conducting the audit; or
            
442

    
    (II)  200 prescription claims; or
            
443

    
    (B)  the number of claims for which the entity has substantiated or documented
            
444

    
discrepancies.
            
445

    
    (4)  An entity may not:
            
446

    
    (a)  include dispensing fees in the calculations of overpayments;
            
447

    
    (b)  recoup funds for a clerical or record keeping error in a required document unless:
            
448

    
    (i)  the entity can provide proof of intent to commit fraud; or
            
449

    
    (ii)  the clerical error resulted in financial harm to the entity or a consumer;
            
450

    
    (c)  collect any funds, charge-backs, or penalties until the audit and all appeals are final;
            
451

    
    (d)  charge interest on disputed claims during the audit and any appeals to the audit;
            
452

    
    (e)  receive payment for the audit based on a percentage of the amount recovered in the
            
453

    
audit; or
            
454

    
    (f)  except when required by state or federal law, share audit information or pharmacy
            
455

    
records with another entity that is conducting a subsequent or new audit of the pharmacy.
            
456

    
    (5)  A pharmacy subject to an audit may use the following records to validate a claim
            
457

    
for a prescription, refill, or change in a prescription:
            
458

    
    (a)  electronic or physical copies of records of a health care facility, or a health care
            
459

    
provider with prescribing authority; and
            
460

    
    (b)  any prescription that complies with state law.
            
461

    
    (6) (a)  An entity that audits a pharmacy shall provide the pharmacy with a preliminary

            
462


    
audit report, delivered to the pharmacy or its corporate office of record within 60 days after
            
463

    
completion of the audit.
            
464

    
    (b)  A pharmacy has 30 days following receipt of the preliminary audit report to
            
465

    
respond to questions, provide additional documentation, and comment on and clarify findings
            
466

    
of the audit.
            
467

    
    (7)  If an audit results in the dispute or denial of a claim, the entity conducting the audit
            
468

    
shall allow the pharmacy to re-submit a claim using any commercially reasonable method,
            
469

    
including fax, mail, or electronic claims submission.
            
470

    
    (8) (a)  Within 120 days after the completion of the appeals process under Subsection
            
471

    
(9), a final audit report shall be delivered to the pharmacy or its corporate office of record, and
            
472

    
to the health benefit plan for whom the audit was conducted.
            
473

    
    (b)  The final audit report shall include a disclosure of any money recovered by the
            
474

    
entity that conducted the audit.
            
475

    
    (9) (a)  An entity that audits a pharmacy shall establish a written appeals process for
            
476

    
appealing a preliminary audit report and a final audit report, and shall provide the pharmacy
            
477

    
with notice of the written appeals process at the time the notice of audit is provided to the
            
478

    
pharmacy.
            
479

    
    (b)  The appeals process under Subsection (9)(a) shall offer the pharmacy the option to
            
480

    
submit an appeal of the final audit report:
            
481

    
    (i)  directly to the health benefit plan;
            
482

    
    (ii)  to mediation; or
            
483

    
    (iii)  to a civil action.
            
484

    
    (10)  A pharmacy or pharmacist injured as a result of a violation of this section may
            
485

    
bring a civil action against the person, corporation, or business entity that violated this section
            
486

    
for recovery of damages occurring as a result of the violation.




 Legislative Review Note
    as of   1-3-12  10:49 AM

 Office of Legislative Research and General Counsel
[Bill Documents][Bills Directory]









Who represents me?





Remember my Legislators





State Senate
		350 North State, Suite 320
		PO Box 145115
		Salt Lake City, Utah 84114

		Telephone: (801) 538-1035
		Fax: (801) 326-1475



House of Representatives
		350 North State, Suite 350
		PO Box 145030
		Salt Lake City, Utah 84114

		Telephone: (801) 538-1029
		Fax: (801) 326-1544










Home
Mobile Site
Site Map
Calendar
Code / Constitution
House
Senate

Terms of Use/Privacy Policy

ADA
Utah.gov







